Selective inhibitors of TGFβ1
While TGFβ is at the apex of the fibrotic signaling cascade, there are safety concerns linked to off-target effects of neighboring growth factors by non-selective approaches.
Scholar Rock identified potent and selective inhibitors of TGFβ1 signaling at the source of disease in the tissue microenvironment. Preclinical studies show that these highly specific inhibitors can prevent the activation of the growth factor in the fibrotic matrix and may offer a powerful new approach to suppressing pro-fibrotic signaling in multiple organs.
Scholar Rock is collaborating with Gilead with the aim of selecting molecules to be developed as new medicines for patients with fibrotic diseases.
LEARN MORE: Scholar Rock